A Phase 1/2 interventional study of Budoprutug in Systemic Lupus Erthematosus, sponsored by Climb Bio, Inc.. Recruiting at 10 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Climb Bio, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b/2a, open-label study will evaluate budoprutug in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will be evaluated as the change in the number of B cells and immunoglobulins (antibodies) in the blood over time. Budoprutug will be administered as two (2) IV infusions 14 days apart in ascending dose cohorts.
Climb Bio, Inc. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single IV dose at Day 1 and Day 15
Drug: Budoprutug
Single IV dose at Day 1 and Day 15
Drug: Budoprutug
Single IV dose at Day 1 and Day 15
Drug: Budoprutug
Single IV dose at Day 1 and Day 15
Drug: Budoprutug
Single IV dose of study product on Day 1 and Day 15
Also known as: TNT119
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Number of participants experiencing TEAEs, graded per NCI CTCAE v6.0.
Time frame: Up to week 28
Incidence of Clinical Laboratory Abnormalities
Number of participants with clinically significant laboratory abnomalities.
Time frame: Up to week 28
Incidence of dose-limiting toxicities (DLTs)
Number of incidences of dose-limiting toxicities (DLTs)
Time frame: up to 28 weeks
Change from Baseline in Systolic Blood Pressure
Mean change from baseline in diastolic blood pressure (mmHg).
Time frame: Up to week 28
Change from Baseline in Diastolic Blood Pressure
Mean change from baseline in systolic blood pressure (mmHg).
Time frame: up to 28 weeks
Change from Baseline in Heart Rate
Mean change from baseline in heart rate (bpm).
Time frame: up to 28 weeks
Change from Baseline in Respiratory Rate
Mean change from baseline in respiratory rate
Time frame: up to 28 weeks
Change from Baseline in Body Temperature
Mean change from baseline in body temperature (°C)
Time frame: up to 28 weeks
Change from Baseline in PR Interval
Mean change from baseline in PR interval (ms)
Time frame: up to 28 weeks
Change from Baseline in QRS Duration
Mean change from baseline in QRS duration (ms)
Time frame: up to 28 weeks
Change from Baseline in QT Interval
Mean change from baseline in QT interval (ms)
Time frame: up to 28 weeks
Change from Baseline in QTc Interval
Mean change from baseline in corrected QT interval (QTc)
Time frame: up to 28 weeks
Area Under the Curve (AUC)
Measurement of the area under the drug concentration-time curve
Time frame: Up to week 28
Terminal Half-Life (T1/2)
Measurement of the terminal half-life in days
Time frame: Up to week 28
Incidence of Anti-Drug Antibodies (ADAs)
Number of participants with detectable ADAs.
Time frame: Up to week 28
ADA Titer Over Time
Measurement of ADA titer over time
Time frame: Up to week 28
Change from Baseline in CD20+ B-cell Count
Change in absolute peripheral B-cell count
Time frame: Up to week 28
Change from Baseline in SLEDAI-2K Score
Measurement of change in SLEDAI-2K score from baseline
Time frame: up to 28 weeks
Change from Baseline in Urine Protein Creatinine Ratio (UPCR)
Measurement of change in UPCR from baseline
Time frame: up to 28 weeks
Not enrolling at this site.
Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budoprutug
Climb Bio, Inc.